Page 99

House Bill No. 5506

Public Act No. 22-118 99 of 739

deprescribed, the qualified pharmacist or qualified pharmacists shall notify the [treating physician or advanced practice registered nurse] prescribing practitioner of such discontinuance or deprescribing [no] not later than twenty-four hours [from the time of such discontinuance or deprescribing] after such drug therapy is discontinued or deprescribed. Each written protocol or collaborative drug therapy care plan developed, pursuant to [the] a collaborative drug therapy management agreement or collaborative drug therapy management policy, shall contain detailed direction concerning the actions that the qualified pharmacist or qualified pharmacists may perform for [that] the patient [. The] or patient population. Such written protocol or collaborative drug therapy care plan shall include, but need not be limited to, (1) the specific drug or drugs, therapeutic class of drug or classes of drugs, or devices to be managed by the qualified pharmacist or qualified pharmacists, (2) the terms and conditions under which drug therapy may be [implemented] initiated, modified, continued, discontinued or deprescribed, or use of a device may be initiated, continued or discontinued, or a device may be deprescribed, (3) the conditions and events upon which the qualified pharmacist is, or qualified pharmacists are, required to notify the [physician or advanced practice registered nurse, and] prescribing practitioner, (4) the laboratory tests that may be ordered, and (5) a definition of the patient population included in such written protocol or collaborative drug therapy care plan. All activities performed by the qualified pharmacist or qualified pharmacists in conjunction with the protocol or collaborative drug therapy care plan shall be documented in the patient's medical record [. The pharmacist shall report any encounters within the scope of the collaborative drug therapy management agreement within thirty days to the physician or advanced practice registered nurse regarding the patient's drug therapy management or document such information within a shared medical record. The] in accordance with the prescribing practitioner's policies or, in the case of a care-giving institution, all applicable care-giving institution policies.